Video

Dr. Hamid on the Evolving Treatment of Immunotherapy in Patients With Solid Tumors

Author(s):

Omid Hamid, MD, discusses the evolving treatment of immunotherapy in patients with solid tumors.

Omid Hamid, MD, director, Melanoma Program, Cedars-Sinai Medical Center, chief, Translational Research and Immunotherapy, director, Melanoma Therapeutics, Phase I Immuno-Oncology Program, The Angeles Clinic and Research Institute, discusses the evolving treatment of immunotherapy in patients with solid tumors.

Immunotherapy options for the treatment of solid tumors has expanded beyond checkpoint inhibitors alone, Hamid says. Adoptive T-cell regimens and T-cell redirector therapeutics have expanded the toolbox of immunotherapy options, Hamid explains.

Along with establishing a foothold in the treatment landscape, novel regimens also present the opportunity to investigate combination therapies, Hamid continues. This gives investigators hope of solving issues currently associated with primary refractoriness and low response rates, Hamid concludes.

Related Videos
Jonathan Spicer, MD, PhD, FRCS
Daniel DeAngelo, MD, PhD
Marc J. Braunstein, MD, PhD, associate professor, Department of Medicine, co-director, Hematology-Oncology System, New York University (NYU) Grossman Long Island School of Medicine
Douglas W. Sborov, MD, MS, associate professor, Department of Internal Medicine—Division of Hematology and Hematologic Malignancies; director, Hematology Disease Center and Plasma Cell Dyscrasias Program, the University of Utah Huntsman Cancer Institute
Bradley C. Carthon, MD, PhD
David C. Fisher, MD
Alan Tan, MD
Binod Dhakal, MD
Sheldon M. Feldman, MD
Yair Lotan, MD, UT Southwestern Medical Center